Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för iron(III) citrate monohydrate. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

9 träffar

Bibliografisk träff 2019-06-20

Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study.

Yokoyama K, Fukagawa M, Akiba T, Nakayama M, Ito K, Hanaki K, Wolf M, Hirakata H.

Sci Rep · research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1038/s41598-019-45335-4

Bibliografisk träff 2019-04-29

Hepcidin-25/erythroferrone ratio predicts improvement of anaemia in haemodialysis patients treated with ferric citrate hydrate.

Hara M, Nakamura Y, Suzuki H, Asao R, Nakamura M, Nishida K, Kenmotsu S, Inagaki M, Tsuji M, Kiuchi Y, Ohsawa I, Goto Y, Gotoh H.

Nephrology (Carlton) · journal article; observational study · DOI 10.1111/nep.13495

Bibliografisk träff 2019-02-19

Regional prescription surveillance of phosphate binders in the western Saitama area: the substantial role of ferric citrate hydrate in improving serum phosphorus levels and erythropoiesis.

Amano H, Ohno Y, Inoue T, Tomori K, Ohama K, Okada H.

Clin Exp Nephrol · comparative study; journal article; observational study · DOI 10.1007/s10157-019-01715-8

Bibliografisk träff 2018-06-06

Ferric Citrate Decreases Fibroblast Growth Factor 23 and Improves Erythropoietin Responsiveness in Hemodialysis Patients.

Maruyama N, Otsuki T, Yoshida Y, Nagura C, Kitai M, Shibahara N, Tomita H, Maruyama T, Abe M.

Am J Nephrol · multicenter study; randomized controlled trial; journal article · DOI 10.1159/000489964

Bibliografisk träff 2017-11-27

Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.

Iguchi A, Yamamoto S, Yamazaki M, Tasaki K, Suzuki Y, Kazama JJ, Narita I.

Clin Exp Nephrol · randomized controlled trial; journal article · DOI 10.1007/s10157-017-1510-x

Bibliografisk träff 2017-11-03

Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide.

Nakayama M, Tani Y, Zhu WJ, Watanabe K, Yokoyama K, Fukagawa M, Akiba T, Wolf M, Hirakata H.

Kidney Int Rep · research-article; journal article · DOI 10.1016/j.ekir.2017.10.016

Bibliografisk träff 2017-01-05

Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate.

Yokoyama K, Fukagawa M, Akiba T, Nakayama M, Otoguro T, Yamada K, Nagamine Y, Fishbane S, Hirakata H.

Kidney Int Rep · research-article; journal article · DOI 10.1016/j.ekir.2016.12.005

Bibliografisk träff 2015-01-01

[Iron, aluminum, and lanthanum-based drugs for treatment of hyperphosphatemia].

Matsumura K.

Yakugaku Zasshi · review; journal article · DOI 10.1248/yakushi.14-00227-1

Bibliografisk träff 2014-09-26

Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity.

Gupta A.

Pharmaceuticals (Basel) · discussion; journal article · DOI 10.3390/ph7100990